Lung neuroendocrine tumors are a heterogeneous subtype of pulmonary cancers
representing approximately 20% of all lung cancers, including small-cell lung cancer …

Large cell neuroendocrine carcinoma (LCNECs) and small cell lung carcinomas (SCLCs)
are high-grade neuroendocrine carcinomas of the lung with very aggressive behavior and …

Background The optimal treatment of large-cell neuroendocrine carcinoma (LCNEC) of the
lung remains unclear. Here, our primary objective was to assess the efficacy of cisplatin …

Introduction We conducted a phase II study of combination chemotherapy with irinotecan
(CPT) and cisplatin (CDDP) in patients with advanced large-cell neuroendocrine carcinoma …

Large cell neuroendocrine carcinoma of the lung (LCNEC) is a rare and highly aggressive
type of lung cancer, with a complex biology that shares similarities with both small-cell lung …

Large-cell neuroendocrine carcinomas of the lung (LCNECs) are rare tumors representing 1–
3% of all primary lung cancers. Patients with LCNEC are predominantly male, older, and …

Background Large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive cancer
with a dismal prognosis. The majority of cases occur in the lung and the gastrointestinal …

E-cadherin plays a major role in cell–cell adhesion and inactivating germline mutations in its
encoding gene predispose to hereditary diffuse gastric cancer. Evidence indicates that aside …

High-grade neuroendocrine carcinomas of the lung are classified into two categories: large
cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC). While …

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive
malignancy that is strongly linked to smoking and notoriously difficult to diagnose and treat …